Vyndaqel

Vyndaqel (tafamidis) is an oral medication used for transthyretin amyloidosis. It helps stabilize transthyretin protein to slow disease progression. This EU-sourced treatment is taken once daily. A trusted option for hereditary transthyretin-mediated amyloidosis management.

Vyndaqel is prescribed for transthyretin amyloidosis, a condition where abnormal protein builds up and damages organs. It is used to treat adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce symptoms and slow disease progression. This medication is also used for transthyretin amyloidosis polyneuropathy (ATTR-PN) to manage nerve damage. It is not a cure but helps maintain quality of life.

Vyndaqel works by stabilizing the transthyretin protein, preventing it from misfolding and forming harmful deposits. Patients may experience reduced symptoms such as fatigue, numbness, or heart-related issues over time. Regular use supports better mobility and daily functioning. Individual responses vary based on disease stage and overall health.

Vyndaqel should be taken exactly as prescribed by a healthcare provider. Inform your doctor about all medications and medical conditions before starting treatment. Regular liver function tests are recommended during therapy. Avoid sudden changes in dosage without medical guidance. Keep this medication stored in a cool, dry place away from direct sunlight.

Vyndaqel may interact with medications that affect liver enzymes, such as certain antibiotics or antifungals. Combining it with alcohol or herbal supplements could alter its effectiveness. Always consult a healthcare provider before starting new medications while on Vyndaqel. Inform your doctor about all over-the-counter and prescription drugs to prevent potential interactions.